IPP Bureau
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
By IPP Bureau - June 24, 2022
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
MEI Pharma appoints Anne Frese as Chief People Officer
By IPP Bureau - June 24, 2022
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Mandaviya chairs high level meeting to review COVID-19 status
By IPP Bureau - June 24, 2022
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
Silo Pharma expands license agreement and patent portfolio
By IPP Bureau - June 24, 2022
Silo enters into commercial evaluation license agreement for next generation liposomes
Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
By IPP Bureau - June 24, 2022
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Rivaroxaban approved in Japan for patients with PAD after revascularisation
By IPP Bureau - June 24, 2022
It´s the first trial to demonstrate the benefits of dual pathway inhibition
CPC Scientific announces new California peptide API manufacturing facility
By IPP Bureau - June 24, 2022
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Merck KGaA doubles HPAPI production capacity in Wisconsin
By IPP Bureau - June 24, 2022
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
By IPP Bureau - June 23, 2022
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Glenmark Pharmaceuticals to address USFDA’s observation
By IPP Bureau - June 23, 2022
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Alembic Pharmaceuticals shows growth in May 2022
By IPP Bureau - June 23, 2022
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
Avni announces subscription model menstrual hygiene products
By IPP Bureau - June 23, 2022
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Piramal Pharma Solutions appoints Herve Berdou as COO
By IPP Bureau - June 23, 2022
Brings 25 years of global operations and supply chain experience to Piramal
Nippon Express launches new transport service using environmental-friendly isothermal packaging
By IPP Bureau - June 23, 2022
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
Indian Pharma Post organizes e-Conference on ‘Role of Digitalization in Pharma Sector’ June 24
By IPP Bureau - June 23, 2022
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
